Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
23 hedge funds and large institutions have $1.1M invested in Vyant Bio, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 3 closing their positions.
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
4% less funds holding
Funds holding: 24 → 23 (-1)
25% less capital invested
Capital invested by funds: $1.47M → $1.1M (-$368K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$160K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$17.5K |
| 3 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$10.1K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$8.8K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$8.46K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$31.8K |
| 2 |
FCM
Fairbanks Capital Management
Rancho Santa Fe,
California
|
-$20K |
| 3 |
VF
Virtu Financial
New York
|
-$11.7K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
-$6K |
| 5 |
Morgan Stanley
New York
|
-$2.5K |
VYNT Hedge Fund Activity: Q2 2019 in Review
23 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q2 2019, worth a combined $1.1M — down 25% from $1.47M a quarter earlier.
Fund positioning in VYNT was balanced in Q2 2019: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $160K. The largest seller was Perkins Capital Management, cutting an estimated $31.8K.
- 23 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q2 2019, down from 24 in Q1 2019.
- Funds reported $1.1M of Vyant Bio, Inc. Common Stock stock for Q2 2019, down 25% quarter-over-quarter.
- 3 funds opened new Vyant Bio, Inc. Common Stock positions in Q2 2019 and 3 closed out, a net change of 0 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q2 2019 was Renaissance Technologies, an estimated $160K added.
- The largest Vyant Bio, Inc. Common Stock seller in Q2 2019 was Perkins Capital Management, an estimated $31.8K sold.
Based on aggregated 13F filings for Q2 2019.